Abstract
During last years, irinotecan has become registered as a major cytotoxic drug in several tumor types. Since the metabolism of this drug is predominantly made in the liver, administration to patients with liver dysfunctions remains a major problem. Hyperbilirubinemia has been shown to require dose reduction. In addition, gene polymorphism of UGT1A1 was shown to be associated with a higher risk of toxicity. However, studies are still required to optimise the use of irinotecan in patients with liver dysfunctions.
MeSH terms
-
Antineoplastic Agents, Phytogenic / adverse effects*
-
Antineoplastic Agents, Phytogenic / pharmacokinetics
-
Camptothecin / adverse effects
-
Camptothecin / analogs & derivatives*
-
Camptothecin / pharmacokinetics
-
Glucuronosyltransferase / genetics
-
Glucuronosyltransferase / metabolism
-
Humans
-
Hyperbilirubinemia / chemically induced
-
Irinotecan
-
Liver / drug effects
-
Liver / metabolism
-
Liver / pathology*
-
Liver Function Tests
-
Neoplasms / drug therapy*
-
Polymorphism, Genetic
Substances
-
Antineoplastic Agents, Phytogenic
-
Irinotecan
-
Glucuronosyltransferase
-
Camptothecin